Genetic Risk Evaluation in Wet Age-Related Macular Degeneration Treatment Response

被引:9
作者
Chaudhary, Varun [1 ]
Brent, Michael [2 ]
Lam, Wai-Ching [2 ]
Devenyi, Robert [2 ]
Teichman, Joshua [1 ]
Mak, Michael [2 ]
Barbosa, Joshua [1 ]
Kaur, Harneel [1 ]
Carter, Ronald [4 ]
Farrokhyar, Forough [3 ]
机构
[1] McMaster Univ, St Josephs Healthcare Hamilton, Hamilton Reg Eye Inst, Div Ophthalmol,Dept Surg, Hamilton, ON, Canada
[2] Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada
[3] McMaster Univ, Dept Surg, Hamilton, ON, Canada
[4] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada
关键词
Genetics; Visual acuity; Age-related macular degeneration; RANIBIZUMAB TREATMENT; CFH; POLYMORPHISM; DELETION; VARIANT; Y402H; PHARMACOGENETICS; SUSCEPTIBILITY; ASSOCIATION; THERAPY;
D O I
10.1159/000446819
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Objective: To evaluate the pharmacogenetic relationship between CFH haplotypes and single nucleotide polymorphisms (SNPs) with response to ranibizumab treatment for neovascular age-related macular degeneration (nAMD). Patients and Methods: This was a prospective cohort study involving 70 treatment-naive nAMD patients. Patients were genotyped for CFH haplotypes and SNPs in the C3, ARMS2, and mtDNA genes. Visual acuity and central macular thickness were assessed at baseline and during 6 monthly follow-up visits. Multivariate logistic regression was used to determine the association between genotypes and a gain of >= 15 letters at the 6-month endpoint after adjusting for potential confounders. Results: CFH haplotypes were associated with a gain of letters at the 6-month endpoint (p = 0.046). Patients expressing protective haplotypes were more likely to achieve a gain of >= 15 letters relative to the greatly increased risk haplotypes [OR 6.58 (95% CI: 1.37, 31.59)]. Conclusion: CFH is implicated in nAMD patient treatment response to ranibizumab. (C) 2016 S. Karger AG, Basel
引用
收藏
页码:88 / 94
页数:7
相关论文
共 50 条
  • [21] Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration
    Finger, Robert P.
    Wickremasinghe, Sanjeewa S.
    Baird, Paul N.
    Guymer, Robyn H.
    SURVEY OF OPHTHALMOLOGY, 2014, 59 (01) : 1 - 18
  • [22] Genetic and Environmental Risk Factors for Age-Related Macular Degeneration in Persons 90 Years and Older
    Ersoy, Lebriz
    Ristau, Tina
    Hahn, Moritz
    Karlstetter, Marcus
    Langmann, Thomas
    Droege, Katharina
    Caramoy, Albert
    den Hollander, Anneke I.
    Fauser, Sascha
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (03) : 1842 - 1847
  • [23] Genetic association study of age-related macular degeneration in the Spanish population
    Brion, Maria
    Sanchez-Salorio, Manuel
    Corton, Marta
    de la Fuente, Maria
    Pazos, Belen
    Othman, Mohammad
    Swaroop, Anand
    Abecasis, Goncalo
    Sobrino, Beatriz
    Carracedo, Angel
    ACTA OPHTHALMOLOGICA, 2011, 89 (01) : E12 - E22
  • [24] TREATMENT OF AGE-RELATED MACULAR DEGENERATION
    Real Juan, Pablo
    Tartara, Ignacio
    Allemandi, Daniel
    Granero, Gladys
    Palma Santiago, Daniel
    ATENCION FARMACEUTICA, 2011, 13 (03): : 160 - 171
  • [25] Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration
    Yazdi, Mohammad Hossein
    Faramarzi, Mohammad All
    Nikfar, Shekoufeh
    Falavarjani, Khalil Ghasemi
    Abdollahi, Mohammad
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (09) : 1349 - 1358
  • [26] Pharmacological Advances in the Treatment of Age-related Macular Degeneration
    Gil-Martinez, Maria
    Santos-Ramos, Paz
    Fernandez-Rodriguez, Maribel
    Abraldes, Maximino J.
    Jose Rodriguez-Cid, Maria
    Santiago-Varela, Maria
    Fernandez-Ferreiro, Anxo
    Gomez-Ulla, Francisco
    CURRENT MEDICINAL CHEMISTRY, 2020, 27 (04) : 583 - 598
  • [27] PHARMACOGENOMICS OF RESPONSE TO ANTI-VEGF THERAPY IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION
    Dedania, Vaidehi S.
    Grob, Seanna
    Zhang, Kang
    Bakri, Sophie J.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2015, 35 (03): : 381 - 391
  • [28] VEGF Gene Polymorphism and Response to Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration
    dos Reis Veloso, Carlos Eduardo
    Frota de Almeida, Luciana Negrao
    Maria Recchia, Franco
    Pelayes, David
    Nehemy, Marcio Bittar
    OPHTHALMIC RESEARCH, 2014, 51 (01) : 1 - 8
  • [29] Proportion of and Reason for Bevacizumab Usage in the Treatment of Wet Age-related Macular Degeneration
    Yoon, Yi Sang
    Yoon, Won Tae
    Kim, Jong Woo
    Kim, Chul Gu
    Kim, Jae Hui
    JOURNAL OF THE KOREAN OPHTHALMOLOGICAL SOCIETY, 2021, 62 (08): : 1076 - 1083
  • [30] Genetic Risk, Lifestyle, and Age-Related Macular Degeneration in Europe The EYE-RISK Consortium
    Colijn, Johanna M.
    Meester-Smoor, Magda
    Verzijden, Timo
    de Breuk, Anita
    Silva, Rufino
    Merle, Benedicte M. J.
    Cougnard-Gregoire, Audrey
    Hoyng, Carel B.
    Fauser, Sascha
    Coolen, Anthonius
    Creuzot-Garcher, Catherine
    Hense, Hans-Werner
    Ueffing, Marius
    Delcourt, Cecile
    den Hollander, Anneke, I
    Klaver, Caroline C. W.
    OPHTHALMOLOGY, 2021, 128 (07) : 1039 - 1049